Surgery Partners' stock experienced a significant after-hours plunge of 22.61% following the release of its fourth quarter 2025 financial results.
The sharp decline appears to be driven by the company's earnings miss, with Q4 adjusted EPS of $0.12 falling significantly short of the analyst consensus estimate of $0.30. Additionally, the company reported Q4 adjusted EBITDA of $156.9 million, which missed estimates of $169.2 million, indicating margin pressure that impacted full-year performance according to company statements.
While the company reported Q4 revenue of $885 million that beat estimates and announced a $200 million share repurchase program, investors focused on the profitability shortfalls and the company's outlook for operational improvements in 2026.